Visual‐somatosensory integration as a novel behavioral marker of amyloid pathology

by Clinical Neuropsychologist Online | Friday, March 7, 2025 | Dementia

Abstract INTRODUCTION The ability to integrate information across sensory modalities is a vital aspect of everyday functioning and is linked to cognition. Increasing evidence suggests that Alzheimer’s disease (AD) pathology manifests in sensory association areas...

Genetic and pharmacologic enhancement of SUMO2 conjugation prevents and reverses cognitive impairment and synaptotoxicity in a preclinical model of Alzheimer’s disease

by Clinical Neuropsychologist Online | Thursday, March 6, 2025 | Dementia

Abstract INTRODUCTION Amyloid beta oligomers (Aβos) are toxic to synapses and key to the progression of Alzheimer’s disease (AD) and amyloid pathology, representing a target for therapeutic strategies. METHODS Amyloid and small ubiquitin modifier 2 (SUMO2)...

Calcineurin inhibition may prevent Alzheimer disease in people with Down syndrome

by Clinical Neuropsychologist Online | Wednesday, March 5, 2025 | Dementia

Abstract Virtually all people with Down syndrome will develop Alzheimer disease pathology during their lifetime. As Alzheimer disease is the third leading cause of death and a significant factor in end-of-life complications for adults with Down syndrome, identifying...

Systematic review and meta‐analysis of bulk RNAseq studies in human Alzheimer’s disease brain tissue

by Clinical Neuropsychologist Online | Wednesday, March 5, 2025 | Dementia

Abstract We systematically reviewed and meta-analyzed bulk RNA sequencing (RNAseq) studies comparing Alzheimer’s disease (AD) patients to controls in human brain tissue. We searched PubMed, Web of Science, and Scopus for human brain bulk RNAseq studies,...

Parkinsonism in Alzheimer’s disease without Lewy bodies in association with nigral neuron loss: A data‐driven clinicopathologic study

by Clinical Neuropsychologist Online | Wednesday, March 5, 2025 | Dementia

Abstract INTRODUCTION Parkinsonism in patients with Alzheimer’s disease (AD) is often attributed to Lewy-related pathology, given its high comorbidity. In the era of anti-amyloid therapy, recognizing parkinsonism caused by AD pathology is needed to optimize the...

Preclinical Alzheimer’s disease shows alterations in circulating neuronal‐derived extracellular vesicle microRNAs in a multiethnic cohort

by Clinical Neuropsychologist Online | Wednesday, March 5, 2025 | Dementia

Abstract INTRODUCTION Alzheimer’s disease (AD) is the leading cause of dementia, affecting around 50 million individuals worldwide. Brain-derived extracellular vesicles (EVs) can cross the blood–brain barrier carrying neuron-specific molecules, such as microRNAs...